Navigation Links
NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs
Date:7/6/2009

NEW YORK, July 6 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has appointed Alan G. Harris, M.D., Ph.D., FACP, FRCP, as the Company's Vice President of Drug Development and Regulatory Affairs.

Among his responsibilities in this position will be overseeing NeoStem's therapeutic development activities and interfacing with the Chairman of the Scientific Advisory Board to assist in the execution of the Company's scientific vision. This will include overseeing the Company's regulatory activities, working to advance NeoStem's intellectual property portfolio and licensed technologies, assisting in the development of a chronic wound care program and developing a regulatory pathway for commercializing stem cell therapy, including assisting in developing very small embryonic like (VSEL) stem cell therapy in multiple clinical indications. Upon the completion of the Company's proposed acquisition of a 51% interest in Suzhou Erye Pharmaceuticals Company, Ltd., which the Company anticipates closing no later than the fourth quarter of 2009, Dr. Harris is expected to assist in bringing new drugs to China to enhance Erye's pipeline in an effort to increase revenues and provide a higher margin business through their already established 30 province distribution.

Dr. Harris has over 20 years of experience working in clinical drug development in multiple therapeutic areas in the pharmaceutical and biotechnology industries, having conducted and overseen numerous clinical trials in over 30 countries including China. He was recently Senior VP of R&D and Chief Medical Officer at NPS Pharmaceuticals in NJ, where he successfully launched two Phase III registration programs in Gastroenterology and Endocr
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NeoStem, Inc. Comments on Recent Selling Pressure
2. Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
3. Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years
4. Celleration Appoints Mark T. Wagner President and Chief Executive Officer
5. XLHealth Appoints New Vice President of Contracting and Provider Relations
6. Wisconsin Tobacco Tax Increase Is Positive Step for Health, but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs
7. Verathon Inc. Appoints Kendall Stever as Chief Financial Officer
8. Tyco Electronics Appoints Cuong Do as Senior Vice President, Corporate Strategy & Business Development
9. Symmetry Medical Appoints Chairman and Two Directors
10. GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director
11. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...AM,Ala.,Nov.24/PRNewswire-FirstCall/--HealthSouthC...ateintheBankofAmericaMerrillLynch2009CreditConfere...rVicePresidentandTreasurerEdFaywillbespeakingonThu...ewebcastliveandwillbeavailableat http://investor.h... AboutHealthSouth ,, HealthSouthisthenation,sl...
(Date:11/24/2009)...at pose choking hazard, are too loud, or contain d...(HealthDay News) -- As the holiday shopping season...toys are still being sold in stores across the Uni... annual Trouble in Toyland report, released Tues...RG). , The report focuses on toys that pose a c...
(Date:11/24/2009)...ibutes to the falls that plague older adults, stud...y News) -- Falls are a leading cause of death amon...chronic pain contributes to those accidents. , ... weakness, and is associated with mobility limitat...hors wrote. , "Chronic pain, no matter how we m...
(Date:11/24/2009)...n example, study finds no added use but higher cos... -- Direct-to-consumer drug ads may contribute to ...at examined sales of the widely used antiplatelet ...ta from 1999 to 2005 for 27 state Medicaid program...opidogrel did not increase people,s use of the dru...
(Date:11/24/2009)...Nov.24/PRNewswire-USNewswire/--Thereisanewgameinto...reduction,offeringpragmaticandrealisticstrategiesw...ed.SpearheadingthismovementisagroupcalledHAMS--Har...AMSisafree-of-charge,lay-ledsupportandinformationa...nstituteonAlcoholAbuseandAlcoholismtellsusthatonly...
Breaking Medicine News(10 mins):Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3Health News:Chronic Pain Trips Up Seniors 2Health News:Chronic Pain Trips Up Seniors 3Health News:Advertising to Consumers May Raise Drug Prices 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2
...ernors and Mayors Support Event, ALEXANDRIA, Va.,...ealthcare Decisions Day (NHDD), will be the larges... professionals about,advance healthcare planning.,...are Decisions Day. "All Americans should use April...
...hm-Stecher, assistant professor in food science an... with tiny particles. His latest research project ...ver nanoparticles to improve the safety of the wor...such as microbe-resistant fabrics or non-biofoulin...
...il 10 Hooper Holmes,(Amex: HH ) today announced ... Chief Executive Officer and that Benjamin A. Curr...ctors. Mr. Bubbs, who has been a member of the,Boa...usly been named Chairman-Elect,continues as Chairm...
...fied opinion in Type II examination by independent...LLE, Colo., April 10 GHX has received an,unqualif...of its first Type,II SAS 70 compliance audit. The ...ed GHX,s exchange services, which,enable more than...
...y David Spiegel of Faculty of 1000 Medicine ( www....ween depression care management and survival rates...nt and well-conducted study of the effects of trea... sciences at Stanford University, Spiegel evaluate...
...ntries for the eighth,annual Michael E. DeBakey Jo...iomedical Research (FBR) and named after FBR,s cha...s open to all professional journalists whose repor...Dr. DeBakey,s many inventions and innovations have...
Other Medicine News:Health News:National Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally 2Health News:Iowa State University researcher looks to use nanoparticles for food safety 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:GHX Achieves SAS 70 Compliance 2Health News:DeBakey Awards to Recognize Excellence in Biomedical Research Journalism 2
(Date:11/24/2009)...rstCall/--NeurocrineBiosciences,Inc.(Nasdaq: NBIX ...ecutiveOfficerofNeurocrineBiosciences,willbepresen...einNewYork. ,, ThelivepresentationtakesplaceTue....m.PacificTime(PT).Thepresentationwillbesimultaneo... http://www.neurocrine.com . ,, Ifyouareunablet...
(Date:11/24/2009)...Newswire/--SatelliteHealthcare,oneofthenation,sfir...ajorsponsorofnephrologyresearch,todayannounceditsf...lahinhisefforttosupporttheSanJosehomelessthisThank...ulcareerasachefforthepast20years.ButNasrallah,slif...edwithEndStageRenalDisease(ESRD).Thediagnosisirrev...
(Date:11/24/2009)...rstCall/--Orexigen®Therapeutics,Inc.(Nasdaq: ...entofobesity,todayannouncedthatonNovember18,2009th...rsgrantedaninducementstockoptiontopurchase200,000s...pointedHeadoftheGlobalContraveProgram. ,, Thest...extentpermittedbylawandhasanexercisepricepersharee...
Breaking Medicine Technology:Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 3Fate Therapeutics Closes 2430 Million Series B Financing 14844 1Fate Therapeutics Closes 2430 Million Series B Financing 14844 2Fate Therapeutics Closes 2430 Million Series B Financing 14844 3Fate Therapeutics Closes 2430 Million Series B Financing 14844 4Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3China Medicine Announces Strong Third Quarter 2009 Results 6275 1China Medicine Announces Strong Third Quarter 2009 Results 6275 2China Medicine Announces Strong Third Quarter 2009 Results 6275 3China Medicine Announces Strong Third Quarter 2009 Results 6275 4China Medicine Announces Strong Third Quarter 2009 Results 6275 5China Medicine Announces Strong Third Quarter 2009 Results 6275 6China Medicine Announces Strong Third Quarter 2009 Results 6275 7China Medicine Announces Strong Third Quarter 2009 Results 6275 8China Medicine Announces Strong Third Quarter 2009 Results 6275 9China Medicine Announces Strong Third Quarter 2009 Results 6275 10China Medicine Announces Strong Third Quarter 2009 Results 6275 11China Medicine Announces Strong Third Quarter 2009 Results 6275 12China Medicine Announces Strong Third Quarter 2009 Results 6275 13China Medicine Announces Strong Third Quarter 2009 Results 6275 14China Medicine Announces Strong Third Quarter 2009 Results 6275 15
...., May 9 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WY...inistration,s (FDA),San Juan District Office has i...ion of its Guayama, Puerto Rico manufacturing,faci... of the site.,The new classification means that an...ed by the Company or do not merit any further,regu...
...taminated with Diethylene Glycol,(DEG) Remains a P..., Md., May 4, 2007-The U.S. Food and Drug,Administ...rs,suppliers, drug repackers, and health professi...gilant in assuring that glycerin, a,sweetener comm...,prescription drug products, is not contaminated w...
Other Medicine Technology:FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 2FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 3FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2
511 Lightweight Pneumatic Conserver
...Conserver., ,Offers an average 5:1 increase in us...standard cannula. , ,The combination of the OXYMA...ulatory oxygen patients a superior alternative to ...warranty. , ,NOTE: Each model has passed the ...
WAVE 6203
...afts For Insertion Through A 1.0mm Incision., ,... Improved Ergonomics., ,Curved Shafts F...s For Improved Sub-Incisional Flap Purchase., ,...ring Sterilization., ,Reusable, Autoclaveable,...
Medicine Products: